Ocean Biomedical is currently working to advance five powerful assets in our discovery portfolio, with potential to have substantial impact in the treatment and prevention of malaria, the treatment of Pulmonary fibrosis, and the treatment of non-small cell lung cancer. Both of these assets have been licensed from top research physicians at Brown University’s Alpert School of Medicine, including the school’s Dean of Medicine, Dr. Jack Elias, and their Chair of Pathology and Laboratory Medicine, Dr. Jake Kurtis. 

Ocean Biomedical’s malaria assets are the product of decades of research by Dr. Kurtis, including groundbreaking discoveries on parasite cell apoptosis recently published in the Journal Nature. Based on these findings, we are working towards Phase 1 trials of a novel malaria vaccine in mid 2021. We are also working towards developing a whole new class of therapeutic treatments for malaria with Phase 1 trials slated for mid 2021.

Our current Oncology assets are built on the work of Dr. Jack Elias, focused on utilizing Anti-Chitenase 1 to reduce fibrosis in the lungs and potentially treat Hermansky-Pudlak Syndrome, both slated for Phase 1 testing in 2022.  Dr. Elias’s work also includes novel approaches to treating lung cancer using Anti-Chitinase 3/1 and a Chitinase 3/1/PD1 Bi-specific approach, slated for Phase 1 trials in 2022, and 2023 respectively.

With each of these assets, Ocean Biomedical’s team of experienced biopharma executives are working closely with our scientists to move their research forward as efficiently as possible, smoothing the pathways for laboratory and regulatory progress.